Relapsed ovarian cancer: Rucaparib maintains therapeutic advantage analysis

ARIEL3, a phase III randomized, placebo-controlled trial reported by Oza and others at princess Margaret Cancer Center in Canada, showed significant differences between quality-of-life-adjusted progression-free lifetime (QA-PFS) and quality-of-life-adjusted asymptomatic/non-toxic time (Q-TWiST) confirmed Rucaparib's advantage over placebo in all predefined queues.
(J Clin Oncol. doi:10.1200/JCO.19.03107) Rucaparib is the world's first PARP inhibitor for third-line treatment of ovarian cancer, an ex post facto exploratory analysis from Rucaparib Maintenance Therapy compared to placebo Phase III.
patients with platinum-sensitive, relapsed ovarian cancer were randomly assigned Rucaparib (600 mg, twice a day) or a placebo.
follow-up as of April 15, 2017.
In some populations, Rucaparib was significantly longer than the placebo average QA-PFS, including intentional treatment queues (ITT: 375 in rucaparib group, 189 in placebo group; difference of 6.28 months), BRCA mutation queue (130 and 66 cases; difference 9.37 months), iso-recombination defect (HRD) queue (236 and 118; difference was 7.93 months), BRCA wild type / low he clutter loss (LOH) patient subgroup (107 and 54 cases; difference was 2.71 months).
≥ level 3 adverse events in treatment defined TOX, the difference between ITT queue, BRCA mutation queue, HRD queue, and BRCA wild type / low LOH patient subgroup Q-TWiST (Rucaparib vs. placebo group) was 6.88 months, 9.73 months, 8.11 months, and 3.35 months, respectively.
to define ≥ to TOX using adverse events that occur in selected level 2 treatments, Q-TWiST results also continue to favor Rucaparib.
Zhang Shi former source: Zhang Shi former public number copyright notice: All the text, pictures and audio and video materials marked "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce must indicate "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here